Twist Bioscience (NASDAQ:TWST) underwent analysis by 6 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.

The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.

Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $45.17, along with a high estimate of $52.00 and a low estimate of $37.00. This upward trend is evident, with the current average reflecting a 16.81% increase from the previous average price target of $38.67.

Understanding Analyst Ratings: A Comprehensive Breakdown

The standing of Twist Bioscience among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

To gain a panoramic view of Twist Bioscience's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.

Stay up to date on Twist Bioscience analyst ratings.

All You Need to Know About Twist Bioscience

Understanding the Numbers: Twist Bioscience's Finances

Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.

Revenue Growth: Twist Bioscience displayed positive results in 3M. As of 30 September, 2025, the company achieved a solid revenue growth rate of approximately 16.88%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.

Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -27.41%, the company showcases strong profitability and effective cost control.

Return on Equity (ROE): Twist Bioscience's ROE stands out, surpassing industry averages. With an impressive ROE of -5.71%, the company demonstrates effective use of equity capital and strong financial performance.

Return on Assets (ROA): Twist Bioscience's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -4.22%, the company may face hurdles in generating optimal returns from its assets.

Debt Management: Twist Bioscience's debt-to-equity ratio is below the industry average. With a ratio of 0.16, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.

Analyst Ratings: What Are They?

Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.

Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.

This article was generated by Benzinga's automated content engine and reviewed by an editor.